Alteogen is a leading bio company specializing in next-generation biobetters, biosimilars, and proprietary biologics. They focus on long-acting biobetters, proprietary antibody-drug conjugate, and antibody biosimilars with high complexity.

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.

1961

COM:ALTEOGEN

Alteogen

Last Close

380K

08/11 06:30

Market Cap

14.32T

Beta: -

Volume Today

2.90M

Avg: -

market

industry

website

crunchbase

ipo date

peer of

competitor of

Metrics